The utility of a treatment with nicotinamide or other PARP-1 for AD might be more effective at early stages of the disease, before overt neurodegeneration and the deleterious effects of mitochondrial and exhausted microglial dysfunction are widespread. The gene discussed is PARP1; the disease is Alzheimer disease.